Ameritas Investment Partners’s Quince Therapeutics QNCX Stock Holding History

Ameritas Investment Partners’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8	Closed	-$10K	–	3202
2022 Q1	$10K	Hold	8	–	–	﹤0.01%	2800
2021 Q4	$20K	Hold	8	–	–	﹤0.01%	2650
2021 Q3	$143K	Hold	8	–	–	0.01%	1466
2021 Q2	$83K	Buy	8 +1	+14%	+$8.38K	﹤0.01%	1854
2021 Q1	$50K	Hold	7	–	–	﹤0.01%	2086
2020 Q4	$39K	Hold	7	–	–	﹤0.01%	2130
2020 Q3	$69K	Hold	7	–	–	﹤0.01%	1649
2020 Q2	$64K	Buy	7 +2	+40%	+$18.3K	﹤0.01%	1687
2020 Q1	$45K	Hold	5	–	–	﹤0.01%	1728
2019 Q4	$55K	Buy	5 +4	+400%	+$24.1K	﹤0.01%	1866
2019 Q3	$6K	Hold	1	–	–	﹤0.01%	2902
2019 Q2	$11K	Buy	+1	New	+$5.97K	﹤0.01%	2770

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Ameritas Investment Partners's QNCX Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 8 shares — an estimated $10K sold.

Ameritas Investment Partners first reported a position in QNCX in Q2 2019 and held it in 12 quarters. The position peaked at $143K in Q3 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

Ameritas Investment Partners reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
Ameritas Investment Partners sold 8 Quince Therapeutics shares in Q2 2022, an estimated $10K.
Ameritas Investment Partners first reported a position in Quince Therapeutics in Q2 2019 and held it in 12 quarters.
Ameritas Investment Partners's Quince Therapeutics position peaked at $143K in Q3 2021.
66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.